南新制药：遭证监会立案调查 此前因会计差错更正致业绩“变脸”

Core Viewpoint - Nanxin Pharmaceutical is under investigation by the China Securities Regulatory Commission for suspected violations of annual report information disclosure, leading to the termination of its cash acquisition of Future Pharmaceutical assets due to failure to reach consensus on key terms [1] Financial Adjustments - The company corrected prior accounting errors, resulting in a reduction of 2023 revenue by 24.5397 million yuan, which is 3.4% of the total annual revenue [1] - The correction significantly impacted the company's net profit, changing from a profit of 3.7515 million yuan to a loss of 10.8687 million yuan for 2023, fundamentally altering the profit-loss status [1] - Due to the retrospective adjustment of accounting errors, the company also revised its financial data for multiple reports in 2024, with the Q1-Q3 2024 revenue adjusted from 226.5709 million yuan to 251.1106 million yuan, an increase of 24.5397 million yuan; the net profit for the same period was adjusted from a loss of 71.8361 million yuan to a loss of 57.2159 million yuan [1]